WDR13

Summary

WDR13 (WD repeat domain 13, HGNC:14352) is a protein-coding gene on chromosome Xp11.23, encoding WD repeat-containing protein 13 (Q9H1Z4).

This gene encodes a member of the WD repeat protein family. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by Gly-His and Trp-Asp (GH-WD), which may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. A similar protein in mouse is thought to be a negative regulator of the pancreatic beta cell proliferation. Mice lacking this gene exhibit increased pancreatic islet mass and higher serum insulin levels, and are mildly obese.

Source: NCBI Gene 64743 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability (Limited, GenCC)
• Clinical variants (ClinVar): 100 total
• Phenotypes (HPO): 2
• MANE Select transcript: NM_001347217

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14352
Approved symbol	WDR13
Name	WD repeat domain 13
Location	Xp11.23
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000101940
Ensembl biotype	protein_coding
OMIM	300512
Entrez	64743

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 18 protein_coding, 6 retained_intron, 2 nonsense_mediated_decay

ENST00000218056, ENST00000376729, ENST00000466962, ENST00000470124, ENST00000472440, ENST00000479279, ENST00000482760, ENST00000486125, ENST00000492715, ENST00000492873, ENST00000495575, ENST00000498631, ENST00000888024, ENST00000888025, ENST00000888026, ENST00000888027, ENST00000888028, ENST00000921735, ENST00000921736, ENST00000949617, ENST00000949618, ENST00000949619, ENST00000949620, ENST00000949621, ENST00000949622, ENST00000949623

RefSeq mRNA: 4 — MANE Select: NM_001347217 NM_001166426, NM_001347217, NM_001347219, NM_017883

CCDS: CCDS14302

Canonical transcript exons

ENST00000376729 — 10 exons

Exon	Start	End
ENSE00001920165	48604848	48608869
ENSE00001923566	48597492	48597614
ENSE00003518377	48604272	48604390
ENSE00003524768	48600319	48600626
ENSE00003577767	48599587	48599717
ENSE00003592046	48601784	48601964
ENSE00003636396	48602065	48602206
ENSE00003637696	48599353	48599462
ENSE00003659388	48598717	48598957
ENSE00003672222	48597958	48598037

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.5325 / max 143.2439, expressed in 1821 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196268	19.2777	1812
196271	6.6406	1772
196269	1.6873	1068
196272	1.5703	865
196267	0.9580	224
196270	0.7275	457
196273	0.5353	289
196266	0.1360	53

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	99.13	gold quality
apex of heart	UBERON:0002098	99.11	gold quality
right uterine tube	UBERON:0001302	98.96	gold quality
adenohypophysis	UBERON:0002196	98.89	gold quality
right lobe of thyroid gland	UBERON:0001119	98.72	gold quality
metanephros cortex	UBERON:0010533	98.64	gold quality
lower esophagus mucosa	UBERON:0035834	98.59	gold quality
left lobe of thyroid gland	UBERON:0001120	98.58	gold quality
left ovary	UBERON:0002119	98.53	gold quality
right ovary	UBERON:0002118	98.40	gold quality
body of stomach	UBERON:0001161	98.27	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.24	gold quality
right atrium auricular region	UBERON:0006631	98.22	gold quality
body of uterus	UBERON:0009853	98.22	gold quality
pituitary gland	UBERON:0000007	98.19	gold quality
minor salivary gland	UBERON:0001830	98.15	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.13	gold quality
lower esophagus	UBERON:0013473	98.12	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.11	gold quality
right frontal lobe	UBERON:0002810	98.07	gold quality
left adrenal gland cortex	UBERON:0035825	97.99	gold quality
right adrenal gland cortex	UBERON:0035827	97.99	gold quality
stromal cell of endometrium	CL:0002255	97.98	gold quality
nerve	UBERON:0001021	97.95	gold quality
tibial nerve	UBERON:0001323	97.95	gold quality
right adrenal gland	UBERON:0001233	97.94	gold quality
thyroid gland	UBERON:0002046	97.91	gold quality
endocervix	UBERON:0000458	97.90	gold quality
left adrenal gland	UBERON:0001234	97.88	gold quality
mucosa of transverse colon	UBERON:0004991	97.84	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.49

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

5 targeting WDR13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3135B	98.61	65.33	1470
HSA-MIR-4707-5P	90.95	65.69	110

Literature-anchored findings (GeneRIF, showing 1)

• WDR13: A Novel Gene Implicated in Non-Syndromic Intellectual Disability. (PMID:34946860)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	wdr13	ENSDARG00000022974
mus_musculus	Wdr13	ENSMUSG00000031166
rattus_norvegicus	Wdr13	ENSRNOG00000039587
rattus_norvegicus		ENSRNOG00000062548
caenorhabditis_elegans		WBGENE00021482

Paralogs (1): WDR26 (ENSG00000162923)

Protein

Protein identifiers

WD repeat-containing protein 13 — Q9H1Z4 (reviewed: Q9H1Z4)

All UniProt accessions (4): Q9H1Z4, A0A087WWV5, A0A087X091, A0A087X2H9

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus.

Tissue specificity. Widely expressed.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H1Z4-1	1	yes
Q9H1Z4-2	2

RefSeq proteins (4): NP_001159898, NP_001334146, NP_001334148, NP_060353 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR051350	WD_repeat-ST_regulator	Family

Pfam: PF00400

UniProt features (17 total): repeat 7, modified residue 6, chain 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H1Z4-F1	79.85	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 79, 114, 114, 1, 70, 74

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 124 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GSE45365_NK_CELL_VS_CD8A_DC_UP, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GGGTGGRR_PAX4_03, YY1_Q6, GGCNKCCATNK_UNKNOWN, SREBP1_02, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, YY1_02, ZIC1_01, GOBP_EPITHELIAL_CELL_PROLIFERATION, GGCNNMSMYNTTG_UNKNOWN, CCCNNGGGAR_OLF1_01

GO Biological Process (1): negative regulation of type B pancreatic cell proliferation (GO:1904691)

GO Molecular Function (2): promoter-specific chromatin binding (GO:1990841), protein binding (GO:0005515)

GO Cellular Component (4): nucleoplasm (GO:0005654), plasma membrane (GO:0005886), centriolar satellite (GO:0034451), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
type B pancreatic cell proliferation	1
negative regulation of epithelial cell proliferation	1
regulation of type B pancreatic cell proliferation	1
chromatin binding	1
binding	1
nuclear lumen	1
membrane	1
cell periphery	1
centrosome	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1043 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WDR13	GATA1	P15976	619
WDR13	TBC1D25	Q3MII6	614
WDR13	FTSJ1	Q9UET6	560
WDR13	EBPL	Q9BY08	492
WDR13	JUN	P05412	478
WDR13	WDR89	Q96FK6	461
WDR13	ZNF182	P17025	419
WDR13	RNF34	Q969K3	414
WDR13	TRAPPC5	Q8IUR0	409
WDR13	HSD17B10	Q99714	407
WDR13	PPP1R3F	Q6ZSY5	404
WDR13	GSPT2	Q8IYD1	402
WDR13	ZNF81	P51508	395
WDR13	SPAG17	Q6Q759	393
WDR13	ZCCHC18	P0CG32	386

IntAct

26 interactions, top by confidence:

A	B	Type	Score
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
B3GAT3	GOLIM4	psi-mi:“MI:0914”(association)	0.640
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
EPHA1	EXOC5	psi-mi:“MI:0914”(association)	0.530
ZNRD2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
CDC37	WDR13	psi-mi:“MI:0915”(physical association)	0.400
SH2D3C	TMEM14DP	psi-mi:“MI:0914”(association)	0.350
SH2D3C	ANXA2P2	psi-mi:“MI:0914”(association)	0.350
GIGYF1	DYNC1I1	psi-mi:“MI:0914”(association)	0.350
VCP	SHTN1	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
CAMK2D	PPM1D	psi-mi:“MI:0914”(association)	0.350
EPHA1	ENC1	psi-mi:“MI:0914”(association)	0.350
FTL		psi-mi:“MI:0914”(association)	0.350
PPP2R2B	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
metK	WDR13	psi-mi:“MI:0915”(physical association)	0.000
DSCR9	WDR13	psi-mi:“MI:0915”(physical association)	0.000
RSPH1	WDR13	psi-mi:“MI:0915”(physical association)	0.000
ERG	WDR13	psi-mi:“MI:0915”(physical association)	0.000
DSCAM	WDR13	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (41): WDR13 (Affinity Capture-MS), WDR13 (Affinity Capture-MS), WDR13 (Affinity Capture-MS), WDR13 (Affinity Capture-RNA), WDR13 (Affinity Capture-RNA), WDR13 (Affinity Capture-MS), WDR13 (Two-hybrid), WDR13 (Synthetic Lethality), WDR13 (Affinity Capture-MS), WDR13 (Proximity Label-MS), WDR13 (Affinity Capture-MS), WDR13 (Affinity Capture-MS), WDR13 (Affinity Capture-MS), WDR13 (Affinity Capture-MS), WDR13 (Affinity Capture-MS)

ESM2 similar proteins: A2AHJ4, F1QEB7, O42611, O43815, O55106, O75694, O75717, O94967, P59328, P70483, P79987, Q13112, Q15542, Q3KR73, Q4U2V3, Q5I0B9, Q5R1S9, Q5RF24, Q641K1, Q6DKP5, Q6PCM2, Q6RI45, Q7SYD9, Q802U2, Q8BPM2, Q8C092, Q8CGF6, Q8CID0, Q8IVH8, Q8K1X1, Q8NHY2, Q8QFR2, Q8VDD9, Q8WWQ0, Q91V09, Q921C3, Q924I2, Q99JP0, Q99P88, Q9BZH6

Diamond homologs: A1L271, A4RDD7, B2B5V0, B8AP31, G5EF68, O14435, O14775, O45040, P16520, P18851, P23232, P36408, P49177, P49178, P52287, P54311, P62871, P62872, P62873, P62874, P62881, P62882, P79147, P79959, P93339, P93397, P93398, P93563, Q04225, Q08706, Q40507, Q40687, Q5GIS3, Q5R5W8, Q5RDY7, Q5RF24, Q61011, Q6BSL7, Q6DKP5, Q6FL15

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

100 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1538 predictions. Top by Δscore:

Variant	Effect	Δscore
X:48598955:G:GT	donor_gain	1.0000
X:48598955:GAGG:G	donor_loss	1.0000
X:48598957:GGTG:G	donor_loss	1.0000
X:48598958:G:C	donor_loss	1.0000
X:48598959:T:G	donor_loss	1.0000
X:48599345:A:AG	acceptor_gain	1.0000
X:48599346:T:G	acceptor_gain	1.0000
X:48599349:GCAG:G	acceptor_loss	1.0000
X:48599351:A:AG	acceptor_gain	1.0000
X:48599351:A:C	acceptor_loss	1.0000
X:48599351:AG:A	acceptor_gain	1.0000
X:48599352:G:GC	acceptor_gain	1.0000
X:48599352:GG:G	acceptor_gain	1.0000
X:48599352:GGA:G	acceptor_gain	1.0000
X:48599352:GGAC:G	acceptor_gain	1.0000
X:48599352:GGACT:G	acceptor_gain	1.0000
X:48599458:GACAG:G	donor_gain	1.0000
X:48599459:ACAGG:A	donor_loss	1.0000
X:48599461:AGGTA:A	donor_loss	1.0000
X:48599462:GGTA:G	donor_loss	1.0000
X:48599463:G:C	donor_loss	1.0000
X:48599463:G:GG	donor_gain	1.0000
X:48599464:T:G	donor_loss	1.0000
X:48599575:ATTGG:A	acceptor_gain	1.0000
X:48599577:T:A	acceptor_gain	1.0000
X:48600317:A:AG	acceptor_gain	1.0000
X:48600318:G:GA	acceptor_gain	1.0000
X:48600639:G:GT	donor_gain	1.0000
X:48602054:T:A	acceptor_gain	1.0000
X:48602057:T:A	acceptor_gain	1.0000

AlphaMissense

3170 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:48598031:A:T	D12V	1.000
X:48599672:T:C	F160L	1.000
X:48599674:T:A	F160L	1.000
X:48599674:T:G	F160L	1.000
X:48600333:T:C	F180L	1.000
X:48600335:C:A	F180L	1.000
X:48600335:C:G	F180L	1.000
X:48600468:T:A	W225R	1.000
X:48600468:T:C	W225R	1.000
X:48600481:A:T	N229I	1.000
X:48600496:C:A	S234Y	1.000
X:48601787:G:T	G279W	1.000
X:48601788:G:A	G279E	1.000
X:48601819:C:A	N289K	1.000
X:48601819:C:G	N289K	1.000
X:48601910:T:A	W320R	1.000
X:48601910:T:C	W320R	1.000
X:48602170:T:C	L373P	1.000
X:48604345:A:C	S410R	1.000
X:48604347:C:A	S410R	1.000
X:48604347:C:G	S410R	1.000
X:48604355:G:A	C413Y	1.000
X:48604369:T:C	F418L	1.000
X:48604371:C:A	F418L	1.000
X:48604371:C:G	F418L	1.000
X:48604960:C:A	N462K	1.000
X:48604960:C:G	N462K	1.000
X:48604977:T:C	L468P	1.000
X:48604980:C:A	A469D	1.000
X:48604983:C:A	S470Y	1.000

dbSNP variants (sampled 300 via entrez): RS1000181191 (X:48596219 A>C), RS1000233031 (X:48588376 G>A), RS1000348678 (X:48588801 C>A), RS1000578229 (X:48606886 C>T), RS1000608357 (X:48599033 C>T), RS1000716573 (X:48607221 T>G), RS1000783394 (X:48598281 G>T), RS1000810036 (X:48607436 T>C), RS1001209785 (X:48601267 C>T), RS1002180942 (X:48603118 C>A,T), RS1002273640 (X:48592533 A>C,G), RS1002712757 (X:48602527 C>A), RS1003385850 (X:48596132 C>T), RS1003701815 (X:48595653 C>T), RS1004295124 (X:48597591 C>G)

Disease associations

OMIM: gene MIM:300512 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability	Limited	X-linked

Mondo (3): esophageal atresia (MONDO:0001044), pyloric stenosis (MONDO:0001561), intellectual disability (MONDO:0001071)

Orphanet (0):

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0002032	Esophageal atresia
HP:0002021	Pyloric stenosis

GWAS associations

0 associations (top):

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D004933	Esophageal Atresia	C06.198.330; C06.405.117.260; C16.131.314.330
D017219	Gastric Outlet Obstruction	C06.405.748.340
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D011707	Pyloric Stenosis	C06.405.748.340.690

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	3
sodium arsenite	increases expression	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, increases expression	2
Smoke	increases abundance, increases expression, decreases expression	2
Valproic Acid	decreases expression, increases methylation	2
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
bisphenol A	decreases expression	1
manganese chloride	increases abundance, decreases expression	1
coumarin	decreases phosphorylation	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
perfluorooctane sulfonic acid	increases expression	1
K 7174	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
jinfukang	increases expression	1
MT19c compound	decreases expression	1
Acetaminophen	decreases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Ivermectin	decreases expression	1
Manganese	increases abundance, decreases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Tunicamycin	increases expression	1
Zinc Sulfate	decreases expression	1
Copper Sulfate	increases expression	1
Acrylamide	decreases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2LA	Abcam HeLa WDR13 KO	Cancer cell line	Female

Clinical trials (associated diseases)

256 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00556283	PHASE4	COMPLETED	RCT: STARR vs Biofeedback
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT00226044	PHASE3	COMPLETED	Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT03127345	PHASE2	WITHDRAWN	Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)